Login to Your Account

Clavis, Translational Therapeutics in Antiviral Drug-for-Equity Deal

By Cormac Sheridan

Wednesday, May 18, 2011
Clavis Pharma ASA has gained a small equity stake in Translational Therapeutics Inc. in return for out-licensing its modified version of the antiviral drug ribavirin for applications in cancer. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription